Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia

Jin Hayakawa, Junya Kanda, Yu Akahoshi, Naonori Harada, Kazuaki Kameda, Tomotaka Ugai, Hidenori Wada, Yuko Ishihara, Koji Kawamura, Kana Sakamoto, Masahiro Ashizawa, Miki Sato, Kiriko Terasako-Saito, Shun ichi Kimura, Misato Kikuchi, Rie Yamazaki, Shinichi Kako, Yoshinobu Kanda

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aplastic anemia patients who received rabbit antithymocyte globulin exhibited response and survival rates inferior to those who received horse antithymocyte globulin in several studies. Therefore, we conducted a meta-analysis to compare rabbit and horse antithymocyte globulin as immunosuppressive therapy for aplastic anemia. We searched online databases for studies that compared antithymocyte globulin regimens as first-line treatment for aplastic anemia, including both randomized and non-randomized controlled trials. The early mortality rate at 3 months and overall response rate at 6 months were evaluated. Thirteen studies were included in the analysis. The risk ratio (RR) of early mortality for rabbit vs. horse antithymocyte globulin was 1.33 [95% confidence interval (CI) 0.69–2.57; P = 0.39], with significant heterogeneity. A sensitivity analysis suggested higher early mortality rate in patients who received rabbit antithymocyte globulin. The overall response rate was significantly higher in patients who received horse antithymocyte globulin (RR 1.27; 95% CI 1.05–1.54; P = 0.015). In conclusion, in aplastic anemia patients treated with ATG, early mortality rate was not significantly different in patients receiving horse or rabbit ATG, although a sensitivity analysis showed higher early mortality in the rabbit ATG group. Horse ATG was associated with significantly higher response rate than rabbit ATG.

Original languageEnglish
Pages (from-to)578-586
Number of pages9
JournalInternational Journal of Hematology
Volume105
Issue number5
DOIs
Publication statusPublished - 2017 May 1
Externally publishedYes

Fingerprint

Antilymphocyte Serum
Aplastic Anemia
Horses
Meta-Analysis
Rabbits
Mortality
Therapeutics
Odds Ratio
Confidence Intervals
Immunosuppressive Agents
Survival Rate
Databases

Keywords

  • Aplastic anemia
  • Bone marrow failure
  • Immunosuppressive therapy
  • Meta-analysis

ASJC Scopus subject areas

  • Hematology

Cite this

Hayakawa, J., Kanda, J., Akahoshi, Y., Harada, N., Kameda, K., Ugai, T., ... Kanda, Y. (2017). Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia. International Journal of Hematology, 105(5), 578-586. https://doi.org/10.1007/s12185-017-2179-3

Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia. / Hayakawa, Jin; Kanda, Junya; Akahoshi, Yu; Harada, Naonori; Kameda, Kazuaki; Ugai, Tomotaka; Wada, Hidenori; Ishihara, Yuko; Kawamura, Koji; Sakamoto, Kana; Ashizawa, Masahiro; Sato, Miki; Terasako-Saito, Kiriko; Kimura, Shun ichi; Kikuchi, Misato; Yamazaki, Rie; Kako, Shinichi; Kanda, Yoshinobu.

In: International Journal of Hematology, Vol. 105, No. 5, 01.05.2017, p. 578-586.

Research output: Contribution to journalArticle

Hayakawa, J, Kanda, J, Akahoshi, Y, Harada, N, Kameda, K, Ugai, T, Wada, H, Ishihara, Y, Kawamura, K, Sakamoto, K, Ashizawa, M, Sato, M, Terasako-Saito, K, Kimura, SI, Kikuchi, M, Yamazaki, R, Kako, S & Kanda, Y 2017, 'Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia', International Journal of Hematology, vol. 105, no. 5, pp. 578-586. https://doi.org/10.1007/s12185-017-2179-3
Hayakawa, Jin ; Kanda, Junya ; Akahoshi, Yu ; Harada, Naonori ; Kameda, Kazuaki ; Ugai, Tomotaka ; Wada, Hidenori ; Ishihara, Yuko ; Kawamura, Koji ; Sakamoto, Kana ; Ashizawa, Masahiro ; Sato, Miki ; Terasako-Saito, Kiriko ; Kimura, Shun ichi ; Kikuchi, Misato ; Yamazaki, Rie ; Kako, Shinichi ; Kanda, Yoshinobu. / Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia. In: International Journal of Hematology. 2017 ; Vol. 105, No. 5. pp. 578-586.
@article{f5d91f0b3cc6425fb0a1960da4454916,
title = "Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia",
abstract = "Aplastic anemia patients who received rabbit antithymocyte globulin exhibited response and survival rates inferior to those who received horse antithymocyte globulin in several studies. Therefore, we conducted a meta-analysis to compare rabbit and horse antithymocyte globulin as immunosuppressive therapy for aplastic anemia. We searched online databases for studies that compared antithymocyte globulin regimens as first-line treatment for aplastic anemia, including both randomized and non-randomized controlled trials. The early mortality rate at 3 months and overall response rate at 6 months were evaluated. Thirteen studies were included in the analysis. The risk ratio (RR) of early mortality for rabbit vs. horse antithymocyte globulin was 1.33 [95{\%} confidence interval (CI) 0.69–2.57; P = 0.39], with significant heterogeneity. A sensitivity analysis suggested higher early mortality rate in patients who received rabbit antithymocyte globulin. The overall response rate was significantly higher in patients who received horse antithymocyte globulin (RR 1.27; 95{\%} CI 1.05–1.54; P = 0.015). In conclusion, in aplastic anemia patients treated with ATG, early mortality rate was not significantly different in patients receiving horse or rabbit ATG, although a sensitivity analysis showed higher early mortality in the rabbit ATG group. Horse ATG was associated with significantly higher response rate than rabbit ATG.",
keywords = "Aplastic anemia, Bone marrow failure, Immunosuppressive therapy, Meta-analysis",
author = "Jin Hayakawa and Junya Kanda and Yu Akahoshi and Naonori Harada and Kazuaki Kameda and Tomotaka Ugai and Hidenori Wada and Yuko Ishihara and Koji Kawamura and Kana Sakamoto and Masahiro Ashizawa and Miki Sato and Kiriko Terasako-Saito and Kimura, {Shun ichi} and Misato Kikuchi and Rie Yamazaki and Shinichi Kako and Yoshinobu Kanda",
year = "2017",
month = "5",
day = "1",
doi = "10.1007/s12185-017-2179-3",
language = "English",
volume = "105",
pages = "578--586",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia

AU - Hayakawa, Jin

AU - Kanda, Junya

AU - Akahoshi, Yu

AU - Harada, Naonori

AU - Kameda, Kazuaki

AU - Ugai, Tomotaka

AU - Wada, Hidenori

AU - Ishihara, Yuko

AU - Kawamura, Koji

AU - Sakamoto, Kana

AU - Ashizawa, Masahiro

AU - Sato, Miki

AU - Terasako-Saito, Kiriko

AU - Kimura, Shun ichi

AU - Kikuchi, Misato

AU - Yamazaki, Rie

AU - Kako, Shinichi

AU - Kanda, Yoshinobu

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Aplastic anemia patients who received rabbit antithymocyte globulin exhibited response and survival rates inferior to those who received horse antithymocyte globulin in several studies. Therefore, we conducted a meta-analysis to compare rabbit and horse antithymocyte globulin as immunosuppressive therapy for aplastic anemia. We searched online databases for studies that compared antithymocyte globulin regimens as first-line treatment for aplastic anemia, including both randomized and non-randomized controlled trials. The early mortality rate at 3 months and overall response rate at 6 months were evaluated. Thirteen studies were included in the analysis. The risk ratio (RR) of early mortality for rabbit vs. horse antithymocyte globulin was 1.33 [95% confidence interval (CI) 0.69–2.57; P = 0.39], with significant heterogeneity. A sensitivity analysis suggested higher early mortality rate in patients who received rabbit antithymocyte globulin. The overall response rate was significantly higher in patients who received horse antithymocyte globulin (RR 1.27; 95% CI 1.05–1.54; P = 0.015). In conclusion, in aplastic anemia patients treated with ATG, early mortality rate was not significantly different in patients receiving horse or rabbit ATG, although a sensitivity analysis showed higher early mortality in the rabbit ATG group. Horse ATG was associated with significantly higher response rate than rabbit ATG.

AB - Aplastic anemia patients who received rabbit antithymocyte globulin exhibited response and survival rates inferior to those who received horse antithymocyte globulin in several studies. Therefore, we conducted a meta-analysis to compare rabbit and horse antithymocyte globulin as immunosuppressive therapy for aplastic anemia. We searched online databases for studies that compared antithymocyte globulin regimens as first-line treatment for aplastic anemia, including both randomized and non-randomized controlled trials. The early mortality rate at 3 months and overall response rate at 6 months were evaluated. Thirteen studies were included in the analysis. The risk ratio (RR) of early mortality for rabbit vs. horse antithymocyte globulin was 1.33 [95% confidence interval (CI) 0.69–2.57; P = 0.39], with significant heterogeneity. A sensitivity analysis suggested higher early mortality rate in patients who received rabbit antithymocyte globulin. The overall response rate was significantly higher in patients who received horse antithymocyte globulin (RR 1.27; 95% CI 1.05–1.54; P = 0.015). In conclusion, in aplastic anemia patients treated with ATG, early mortality rate was not significantly different in patients receiving horse or rabbit ATG, although a sensitivity analysis showed higher early mortality in the rabbit ATG group. Horse ATG was associated with significantly higher response rate than rabbit ATG.

KW - Aplastic anemia

KW - Bone marrow failure

KW - Immunosuppressive therapy

KW - Meta-analysis

UR - http://www.scopus.com/inward/record.url?scp=85009250667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009250667&partnerID=8YFLogxK

U2 - 10.1007/s12185-017-2179-3

DO - 10.1007/s12185-017-2179-3

M3 - Article

C2 - 28078653

AN - SCOPUS:85009250667

VL - 105

SP - 578

EP - 586

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 5

ER -